臨床研究等提出・公開システム

A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCESC+)

A Phase 3, Multicenter, Open-Label, Long-Term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX 113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

Gandini Domenica

argenx BV

4-1-3 Kyuutaromachi, Chuo-ku, Osaka, 541-0056, Japan

Japan-Chiken@iconplc.com

Clinical trial contact

ICON Clinical Research GK

4-1-3 Kyutaro-cho, Chuuou-ku, Osaka-city, Osaka, 541-0056, Japan

+81-6-4560-2001

Japan-Chiken@iconplc.com

Complete

Feb. 04, 2022

Interventional

single arm study

open(masking not used)

uncontrolled control

single assignment

treatment purpose

Participants are eligible to be included in the trial only if all of the following criteria apply:
1. Ability to understand the requirements of the trial and provide written informed consent (including consent for the use and disclosure of research related health information), willing and able to comply with the trial protocol procedures (including attending the required trial visits).
2. Participants enrolled in the ARGX-113-2004 trial who completed the 24 week trial period.
Note: If a participant has had an SAE during the ARGX-113-2004 trial, his/her eligibility should be evaluated by the investigator. The decision of enrolling the participant will be evaluated case by case.
3. Agree to use contraceptive measures consistent with local regulations and the following:
- Female participants of childbearing potential must have a negative urine pregnancy test at baseline before receiving IMP.
In addition to the above criteria, for participants who want to continue receiving efgartigimod during an additional 52-week treatment period (only applicable in case efgartigimod is not yet commercially available for patients with primary ITP or available through another patient program for patients with primary ITP), the following criteria apply:
4. Ability to understand the requirements of the additional 52-week treatment period of the trial, to provide written informed consent (including consent for the use and disclosure of research related health information), and to comply with the trial protocol procedures (including required trial visits).
5. Participant has completed a 52-week treatment period.

Participants are eligible to be included in the trial only if none of the following criteria apply:
1. Introduction or continuation of nonpermitted medications during the ARGX 113 2004 trial (such as anti-CD20 therapy, romiplostim, monoclonal antibodies, Fc fusion proteins, or live/live-attenuated vaccines)
2. Use of any other investigational drug or participation in any other investigational trial
3. Known hypersensitivity reaction to efgartigimod PH20 SC or any of its excipients
4. Pregnant or lactating females and those who intend to become pregnant during the trial or within 90 days after last dose of efgartigimod PH20 SC

Both

Primary Immune Thrombocytopenia

Patients will receive ARGX-113 PH20 SC (1000 mg of Efgartigimod Alfa) weekly or biweekly ( continue as in the ARGX-113-2004 trial), and a change in dosing frequency is permitted as from visit 1 (baseline)

To evaluate the safety and tolerability of efgartigimod PH20 SC in adult patients with primary ITP

+81-93-641-5111

Oct. 25, 2021

No

Argentina/Australia/Bulgaria/Chile/China/Colombia/Denmark/France/Georgia/Germany/Greece/Ireland/Israel/Italy/Jordan/Republic of Korea/Latvia/Mexico/New Zealand/Norway/Peru/Poland/Portugal/Romania/Russian Federation/Serbia/South Africa/Spain/Taiwan/Thailand